Recombinant monoclonal antibody to IL12+IL23. Ustekinumab (INN, experimental name CNTO 1275, proprietary commercial name Stelara, Centocor) is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
Figure 1 Skin group population assessments.
a) Skin Physician Global Assessment Responders at week 28. b) Change from baseline in the Sarcoidosis Activity and Severity Index (ΔSASI) score over time. c) Skin domain of the extrapulmonary Physician Organ Severity Tool (ePOST) defined as the percentage of patients with a score improvement of ≥2 points over time. d) Change from baseline in ePOST (ΔePOST) over time. #: nominal p-value versus placebo.
Judson, M. A., Baughman, R. P., Costabel, U., Drent, M., Gibson, K. F., Raghu, G., ... & Wijsenbeek, M. S. (2014). Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. European Respiratory Journal, erj00009-2014.
Figure 2 Mutational analyses of ustekinumab epitope.
(a) Binding of human p40 and epitope variants to ustekinumab. Amino acids E45, E59, D62, M23, L40, and S43 are important IL-12/IL-23p40 residues for ustekinumab binding by ELISA. (b) Ustekinumab binding of p40 mutants (E45A, E59A, D62A, and triple combination) that disrupt antibody/antigen salt bridges by competition ELISA. Hu p40,wild-type humanp40; C177S, chimeric human/mouse p40 protein (hybrid D1-mouseD2-humanD3)with the free Cys177 mutated to Ser. The hybrid D1 domain is a mouse sequence, with all ustekinumab epitope residues substituted at the corresponding positions. (c) Ustekinumab binding of human/mouse swap mutants by competition ELISA. Hu p40 and C177S are the same as (b). P1, P2, and P3 represent human-to-mouse changes in the C177S hybrid D1 domain (G61L, 40LDQSSEVL47→40SDQRHGVI47, and M23T/Q56T, respectively). P1+P2 is a combination of P1 and P2 mutations.
Luo, J., Wu, S. J., Lacy, E. R., Orlovsky, Y., Baker, A., Teplyakov, A., ... & Benson, J. (2010). Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. Journal of molecular biology, 402(5), 797-812.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Ustekinumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL12+IL23. Ustekinumab (INN, experimental name CNTO 1275, proprietary commercial name Stelara, Centocor) is a human monoclonal antibody. It is directed against interleukin 12 and interleukin 23, naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1410-VHH | Recombinant Anti-Human IL12+IL23 VHH Single Domain Antibody | WB, IP, ChiP, Neut, ELISA | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-103 | Anti-Human IL12+IL23 Recombinant Antibody (Briakinumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | IgG1 - lambda |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-063 | Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Ustekinumab), ADCC Enhanced | FuncS, IF, Neut, ELISA, FC | ADCC enhanced antibody |
AFC-TAB-103 | Afuco™ Anti-IL12+IL23 ADCC Recombinant Antibody (Briakinumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-063. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.